Welcome to the Cannabis Countdown. In this week’s rendition, we’ll recap and countdown the top 10 marijuana stock news stories for the week of November 11th – 17th, 2019.
Without further ado, let’s get started.
RWB CEO Brad Rogers Sits Down With James West of Midas Letter
Are U.S. Wealth Managers Morgan Stanley, Merrill Lynch and Wells Fargo Late to the Party?
These banks may be missing out on the real value offered by North American cannabis stocks.
The Two Top Cannabis Markets Go Head-to-Head
U.S. or Canadian pot stocks, which group currently offers investors the most value?
The Company Expects to Report Negative Adjusted EBITDA
Organigram (TSX: OGI) (NASDAQ: OGI) announced preliminary Q4 revenues and provided guidance for revenues of $16.3 million for the fourth quarter. On a quarter over quarter basis revenues declined by 34.14%, from $24.8 million in Q3.
Gross Profit Declined Slightly Compared to Previous Quarter
The Company Reported Revenue Increased 38% Over the Previous Quarter
Medipharm Labs (TSX: LABS) (OTCQX: MEDIF) announced Q3 earnings posting revenues of $43.38 million for the quarter. The firm had a gross profit of $14.75 million, which resulted in a net income of $3.27 million for the period.
With the Earnings Season on the Line, Cannabis Investors Look to Heavy Hitters to Deliver in the Clutch
The heart of the marijuana stocks lineup report earnings this week, Tilray (NASDAQ: TLRY) and Cronos Group (TSX: CRON) (NASDAQ: CRON) results are out, Aurora Cannabis (TSX: ACB) (NYSE: ACB) and Canopy Growth (TSX: WEED) (NYSE: CGC) are on deck.
ACB Stock Plummets More Than 12% in After-Hours Trading
Aurora Cannabis (TSX: ACB) (NYSE: ACB) Q1 earnings also boasted an industry-leading cannabis gross margin.
Multi-Million Dollar Inventory Write-Down and Product Return Charge Add to Canopy’s Woes
These 4 Cannabis Stocks All Have One Thing in Common
Image Sourced from Pixabay